Company Overview

Erasca, Inc. is a U.S.-based clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies targeting RAS/MAPK pathway-driven cancers. The company operates within the biotechnology and oncology therapeutics industries and concentrates primarily on cancers associated with KRAS mutations, one of the most frequently mutated oncogenic drivers in solid tumors. Erasca’s business model is centered on advancing targeted therapies and combination treatment strategies designed to improve outcomes in genetically defined cancer populations.

The company’s primary value drivers are its oncology drug pipeline, intellectual property portfolio, and strategic collaborations. Key programs have included RAS-targeted small molecules and SHP2 inhibitors intended for combination regimens across multiple tumor types. Erasca was founded in 2018 by biotechnology executives and oncology researchers with experience in targeted therapeutics development. Since its founding, the company has expanded through in-licensing agreements, acquisitions of development-stage assets, and strategic partnerships aimed at building a diversified precision oncology portfolio.

Business Operations

Erasca generates no material commercial product revenue as of publicly available filings and operates principally through research and development activities. The company’s operations are organized around advancing its oncology pipeline, including internally developed and licensed therapeutic candidates. Major operational activities include preclinical research, clinical trial execution, regulatory engagement, biomarker development, and manufacturing coordination with third-party contract organizations. Its development portfolio has included programs such as naporafenib, ERAS-0015, and other RAS pathway-directed assets.

The company operates primarily in the United States, with clinical development activities extending internationally through global trial sites and partnerships. Erasca relies on collaborations with biotechnology companies, academic institutions, and contract research organizations to support drug discovery and clinical advancement. Significant partnerships and licensing arrangements have included collaborations with Novartis, Revolution Medicines, and other biotechnology entities associated with RAS-targeted therapies and combination strategies. The company’s core assets consist of proprietary oncology compounds, clinical data packages, and precision medicine capabilities focused on molecularly selected patient populations.

Strategic Position & Investments

Erasca’s strategic direction centers on becoming a leader in RAS-targeted precision oncology by developing combination therapies intended to overcome resistance mechanisms common in RAS-driven cancers. The company has emphasized a “network biology” approach, pursuing multiple therapeutic mechanisms within the RAS/MAPK signaling pathway rather than relying on a single molecular target. Growth initiatives have included expanding its clinical-stage portfolio, initiating biomarker-driven studies, and evaluating combination regimens across solid tumor indications.

A notable strategic transaction was the acquisition of rights associated with naporafenib, a pan-RAF inhibitor originally developed by Novartis, which became a central component of Erasca’s clinical development strategy. The company has also invested in next-generation RAS pathway programs and precision oncology infrastructure intended to support patient selection and combination therapy development. Public filings and investor materials indicate continued focus on KRAS mutation subsets, resistance biology, and therapies addressing unmet needs in metastatic solid tumors.

Geographic Footprint

Erasca is headquartered in San Diego, California, a major biotechnology hub in the United States. Its operational footprint is concentrated primarily in North America, though its clinical programs involve trial sites and research collaborations across multiple international regions. The company’s development activities support participation in global oncology studies involving patients in North America, Europe, and parts of the Asia-Pacific region.

The company’s international presence is driven mainly through clinical operations, licensing arrangements, and strategic collaborations rather than commercial infrastructure. As a clinical-stage biotechnology company, Erasca’s geographic influence is tied to its ability to recruit patients globally for oncology trials and collaborate with multinational pharmaceutical and biotechnology organizations involved in targeted cancer therapeutics.

Leadership & Governance

Erasca was co-founded by biotechnology entrepreneur Jonathan E. Lim, M.D., who has served as a key strategic leader since the company’s inception. Leadership has emphasized building a diversified precision oncology platform focused on scientifically validated cancer pathways and combination-based therapeutic development. Public statements and company materials consistently describe a strategy centered on innovation in RAS biology, disciplined clinical development, and long-term oncology portfolio expansion.

Key executives and leadership figures have included:

• Jonathan E. Lim, M.D. – Chairman, Chief Executive Officer, and Co-Founder
• Andrew J. Eckhardt, M.D. – Chief Medical Officer
• Fred W. Kurland – Chief Financial Officer
• David M. Chacko, M.D. – Former executive leadership and strategic development roles associated with oncology operations
• Mansoor Raza Mirza, M.D. – Member of scientific and clinical advisory leadership associated with oncology expertise

Corporate governance and operational disclosures are documented through SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and investor presentations. Information regarding certain executive transitions and historical leadership roles may vary across reporting periods based on the company’s most recent public filings.